Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

about

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Item

http://www.wikidata.org/entity/Q48022696

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@en

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@nl

type

Item

label

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@en

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@nl

prefLabel

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@en

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@nl

P1476

Novel activating BRAF fusion i ...... Langerhans cell histiocytosis.

@en

P2093

David C Lyden

http://www.w3.org/2001/XMLSchema#string

Ehud Lavi

http://www.w3.org/2001/XMLSchema#string

Eli L Diamond

http://www.w3.org/2001/XMLSchema#string

Ira J Dunkel

http://www.w3.org/2001/XMLSchema#string

Omar Abdel-Wahab

http://www.w3.org/2001/XMLSchema#string

Pallavi Khattar

http://www.w3.org/2001/XMLSchema#string

Ryma Benayed

http://www.w3.org/2001/XMLSchema#string

P2860

Recurrent BRAF mutations in Langerhans cell histiocytosis

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

Risk factors for diabetes insipidus in langerhans cell histiocytosis.

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Genomic Alterations in Langerhans Cell Histiocytosis.

Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis.

Histiocytic neoplasms in the era of personalized genomic medicine.

P31

scholarly article

P356

10.1002/PBC.26699

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28748614

http://www.w3.org/2001/XMLSchema#string

P932

6053915

http://www.w3.org/2001/XMLSchema#string